About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Approaches to Treating Diabetes that Reduce CV Events: How Effective Are DPP-4 Inhibitors, GLP1-Receptor Agonists and SGLT-2 Inhibitors in Reducing MACE and Preventing HF Events?
By
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
FEATURING
Jia Shen
By
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
FEATURING
Jia Shen
336 views
February 5, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
62:17
HeartFlow
Chest Pain in Women: CT's role in making an accurate diagnosis
Feat.
L. Shaw,
M. Gulati
Featured Video
62:17
HeartFlow
Chest Pain in Women: CT's role in making an accurate diagnosis
Feat.
L. Shaw,
M. Gulati
Related Content
AUTOPLAY
ON
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments
Primer on Diabetes Management
Feat.
S. Inzucchi
12:04
Stephen Kopecky
Role of PCSK9 Inhibitors in Diabetes
11:37
ACC 2022 Conference Coverage
ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…
Feat.
P. Heidenreich
28:13
National Lipid Association
New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…
Feat.
R. Mason
11:25
ACC 2023 Conference Coverage
ACC 2023: SGLT2i Use - Dos and Don'ts
Feat.
A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention
Diabetes Treatment Guidelines Finally Have Entered the 21st Century …
Feat.
R. DeFronzo
12:30
Houston Methodist Hospital
Amyloidosis Types and Pathophysiology
Feat.
B. Trachtenberg
15:06
Robert Busch
GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!
26:01
Cardiology Fiesta 2017
Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…
Feat.
R. DeFronzo
12:26
Juan Frias
SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide
27:14
MUSC Cardiology
Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…
Feat.
R. Mentz
15:33
Ken Fujioka
Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…
17:44
Rita Jermyn
SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease
27:24
Cardiometabolic Health Congress (CMHC)
SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes
Feat.
L. Sloan
13:07
Michelle Kittleson
2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …
26:32
Practical Ways to Achieve Targets in Diabetes Care
Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity
Feat.
S. Nissen
09:52
AHA 2022 Conference Coverage
AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…
Feat.
R. Mentz
20:24
Diana Isaacs
Tirzepatide for Type 2 Diabetes
26:49
Diana Isaacs
Tirzepatide Updates
35:16
Scripps Health
HFpEF or Amyloidosis? The Right Therapies for Right Patients
Feat.
M. Kittleson
